BMRN vs. ALNY, UTHR, IONS, ALKS, MDGL, TEVA, BGNE, VTRS, RDY, and GMAB
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), United Therapeutics (UTHR), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Madrigal Pharmaceuticals (MDGL), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical preparations" industry.
BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.
BioMarin Pharmaceutical has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
BioMarin Pharmaceutical received 445 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.15% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.76% of users gave BioMarin Pharmaceutical an outperform vote.
In the previous week, Alnylam Pharmaceuticals had 15 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 27 mentions for Alnylam Pharmaceuticals and 12 mentions for BioMarin Pharmaceutical. Alnylam Pharmaceuticals' average media sentiment score of 0.49 beat BioMarin Pharmaceutical's score of 0.49 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.
BioMarin Pharmaceutical currently has a consensus target price of $107.50, indicating a potential upside of 30.40%. Alnylam Pharmaceuticals has a consensus target price of $215.88, indicating a potential upside of 41.72%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than BioMarin Pharmaceutical.
98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
BioMarin Pharmaceutical has a net margin of 8.31% compared to Alnylam Pharmaceuticals' net margin of -16.58%. BioMarin Pharmaceutical's return on equity of 5.34% beat Alnylam Pharmaceuticals' return on equity.
BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
BioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get BioMarin Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical Competitors List
Related Companies and Tools
